A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With Epilepsy

A Post Marketing Observational Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Epilepsy Patients

The purpose of the study is to evaluate the safety and efficacy of Fycompa® (perampanel) for the adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in participants with epilepsy aged 12 years and older.

Inclusion Criteria:

1. Male and female participants aged 12 years and older
2. Participants who were diagnosed with partial-onset seizures with or without secondarily generalized seizures.
3. Participants who were appropriate to receive Fycompa® as an adjunctive treatment participants starting at Visit 0 according to investigator's judgment.
4. Participants who had provided written informed consent

Exclusion Criteria:

1. Participants not fit to receive Fycompa® as per the latest prescribing information.
2. Participants who were participating in a clinical trial, at the time of the study.
3. Participants who showed evidence of clinically significant disease (cardiac, respiratory, gastrointestinal, renal disease, etc.) that in the opinion of the Investigators could affect the participant's safety or trial conduct.
4. Participants who according to the Investigators would not be able to comply with study procedures.